磷脂酰肌醇蛋白聚糖3(GPC3)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Glypican 3 (GPC3)
DGSX; OCI5; SDYS; SGB; SGBS1; MXR7; Glypican Proteoglycan 3; GTR2-2; Intestinal protein OCI-5; Secreted glypican-3
- 编号SEA971Hu
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 实验方法双抗夹心
- 反应时长3h
- 检测范围0.156-10ng/mL
- 灵敏度最小可检测剂量小于等于0.062ng/mL.
- 样本类型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下载 英文说明书 中文说明书
- 规格 48T96T 96T*5 96T*10 96T*100
- 价格 ¥ 2386 ¥ 3408 ¥ 15336 ¥ 28968 ¥ 238560
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
实验结果图
-
标准曲线图
-
通过ISO 9001、ISO 13485质量体系认证
特异性
本试剂盒用于检测磷脂酰肌醇蛋白聚糖3(GPC3)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的磷脂酰肌醇蛋白聚糖3(GPC3)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 78-99 | 95 |
| EDTA plasma(n=5) | 90-104 | 94 |
| heparin plasma(n=5) | 98-105 | 101 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的磷脂酰肌醇蛋白聚糖3(GPC3)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中磷脂酰肌醇蛋白聚糖3(GPC3)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 79-101% | 78-94% | 82-89% | 88-98% |
| EDTA plasma(n=5) | 88-101% | 78-94% | 94-105% | 78-96% |
| heparin plasma(n=5) | 93-101% | 90-104% | 87-94% | 87-97% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备；
2. 加样（标准品及样本）100µL，37°C孵育1小时；
3. 吸弃，加检测溶液A100µL，37°C孵育1小时；
4. 洗板3次；
5. 加检测溶液B100µL，37°C孵育30分钟；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分钟；
8. 加终止液50µL，立即450nm读数。
实验原理
将磷脂酰肌醇蛋白聚糖3(GPC3)抗体包被于96孔微孔板中，制成固相载体，向微孔中分别加入标准品或标本，其中的磷脂酰肌醇蛋白聚糖3(GPC3)与连接于固相载体上的抗体结合，然后加入生物素化的磷脂酰肌醇蛋白聚糖3(GPC3)抗体，将未结合的生物素化抗体洗净后，加入HRP标记的亲和素，再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的磷脂酰肌醇蛋白聚糖3(GPC3)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值)，计算样品浓度。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPA971Hu02 | 磷脂酰肌醇蛋白聚糖3(GPC3)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA971Hu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA971Hu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)活性蛋白 | Cell culture; Activity Assays. |
| PAA971Hu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)多克隆抗体 | WB; ICC; IHC-P; IHC-F; ELISA. |
| MAA971Hu21 | 磷脂酰肌醇蛋白聚糖3(GPC3)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA971Hu22 | 磷脂酰肌醇蛋白聚糖3(GPC3)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA971Hu24 | 磷脂酰肌醇蛋白聚糖3(GPC3)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA971Hu23 | 磷脂酰肌醇蛋白聚糖3(GPC3)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA971Hu25 | 磷脂酰肌醇蛋白聚糖3(GPC3)单克隆抗体 | WB; IHC; ICC; IP. |
| FAA971Hu82 | 抗磷脂酰肌醇蛋白聚糖3(GPC3)单克隆抗体(异硫氰酸荧光素标记) | Flow cytometry. |
| SEA971Hu | 磷脂酰肌醇蛋白聚糖3(GPC3)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA971Hu | 磷脂酰肌醇蛋白聚糖3(GPC3)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
| 杂志 | 参考文献 |
| Nature and Science | Diagnostic Role of Serum Glypican-3 as a Tumor Marker for Hepatocellular Carcinoma [Sciencepub:10043238] |
| Journal of Applied Pharmaceutical Science | Cytotoxic effects of antiglypican-3 against HepG2 cell line [Ebscohost: Source] |
| Asian Pacific Journal of Cancer Prevention | Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients? [Pubmed: 24460300] |
| Clin Biochem. | Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis [Pubmed: 24362268] |
| Science and Nature | Diagnostic Role of Serum Glypican-3 as Hepatocellular Carcinoma [Zolcat: Source] |
| Alexandria Journal of Medicine | Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis [ScienceDirect: S2090506814000062] |
| J Egypt Natl Canc Inst. | Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. [Pubmed:24841158] |
| European Journal of Pharmacology | Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma [Pubmed:25449037] |
| Hepatobiliary Pancreat Dis Int | Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern [abstract:abstract4525.shtml] |
| Clinical and Molecular Hepatology | Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis [pmc:articles] |
| Wiley | Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment [pubmed:28621802] |
| Biomedicine & Pharmacotherapy | Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and [Pubmed:29669302] |
| Journal of Cancer and Clinical Oncology | Development and Validation of a Two-Site Immunoradiometric assay for Glypican-3 in plasma: Implication in Diagnosis of Hepatocellular Carcinoma [Researchgate:Source] |
| Turkish journal of oncology | Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma [10.5505:tjo.2018.1742] |
| Intensive Care Medicine Experimental | Elevated plasma glypicans are associated with organ failure in patients with infection [Pubmed: 30618011] |
| VALUE OF SERUM GLYPICAN 3 AS A PREDICTIVE TOOL FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) [] | |
| ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C [] |
| Life Sci | Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and … [Pubmed:35640776] |
